An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice.

Virology Journal
Georgina Paz De la RosaMiguel A Gómez-Lim

Abstract

Even though two prophylactic vaccines against HPV are currently licensed, infections by the virus continue to be a major health problem mainly in developing countries. The cost of the vaccines limits wide-scale application in poor countries. A promising strategy for producing affordable and efficient vaccines involves the expression of recombinant immunogens in plants. Several HPV genes have been expressed in plants, including L1, which can self-assemble into virus-like particles. A plant-based, dual prophylactic/therapeutic vaccine remains an attractive possibility. We sought to express in tomato plants chimeric HPV 16 VLPs containing L1 fused to a string of epitopes from HPV 16 E6 and E7 proteins. The L1 employed had been modified to eliminate a strong inhibitory region at the 5' end of the molecule to increase expression levels. Several tomato lines were obtained expressing either L1 alone or L1-E6/E7 from 0.05% to 0.1% of total soluble protein. Stable integration of the transgenes was verified by Southern blot. Northern and western blot revealed successful expression of the transgenes at the mRNA and protein level. The chimeric VLPs were able to assemble adequately in tomato cells. Intraperitoneal administration in mice was...Continue Reading

References

Aug 1, 1993·Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy·W M KastC J Melief
Dec 1, 1995·The Journal of Infectious Diseases·G ChengJ T Schiller
Dec 5, 1995·Proceedings of the National Academy of Sciences of the United States of America·T C WuD M Pardoll
Jul 21, 1997·Virology·M MüllerL Gissmann
Jun 11, 1999·International Journal of Cancer. Journal International Du Cancer·K SchäferI Jochmus
Apr 21, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·P LenzJ T Schiller
May 9, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·M P RudolfW M Kast
Jun 28, 2001·Gynecologic Oncology·M R CastellanosM A Maiman
Mar 29, 2002·Journal of Clinical Pathology·F X BoschK V Shah
Jan 22, 2003·Immunology and Cell Biology·Vithagna KhammanivongGermain J P Fernando
Jul 30, 2003·Journal of Virology·Heribert WarzechaRobert C Rose
Aug 14, 2003·Journal of Virology·Sophia BiemeltMartin Müller
Oct 8, 2003·Current Drug Targets. Infectious Disorders·V G Wilson, G Rosas-Acosta
Dec 22, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jenni M VuolaAdrian V S Hill
Nov 30, 2005·Transgenic Research·Abel Gutiérrez-OrtegaMiguel Angel Gómez-Lim
Jan 21, 2006·International Journal of Cancer. Journal International Du Cancer·Jiahua QianSamir N Khleif
Sep 5, 2006·Vaccine·John T Schiller, Denise Nardelli-Haefliger
May 3, 2007·Annual Review of Plant Biology·Johnathan A Napier
Sep 14, 2007·BMC Biotechnology·Thomas O KohlEdward P Rybicki
Nov 21, 2007·Bulletin of the World Health Organization·F T CuttsL Markowitz

❮ Previous
Next ❯

Citations

Jan 6, 2012·Plant Cell Reports·Chiara LicoLinda Avesani
Nov 8, 2011·Transgenic Research·Heike Mikschofsky, Inge Broer
Oct 29, 2010·Journal of Translational Medicine·Luciano Mariani, Aldo Venuti
Feb 26, 2013·International Journal of Molecular Sciences·Maria Manuela RiganoAmalia Barone
Feb 19, 2013·Expert Review of Vaccines·Joshua W Wang, Richard B S Roden
Feb 25, 2014·Clinics in Dermatology·Lis Ribeiro-Müller, Martin Müller
Dec 4, 2014·Virology Journal·Edward P Rybicki
Jun 13, 2009·International Journal of Cancer. Journal International Du Cancer·Silvia FranceschiCosette M Wheeler
Aug 9, 2013·Plant Biotechnology Journal·Catherine B PineoEdward P Rybicki
Mar 18, 2010·Plant Biotechnology Journal·Edward P Rybicki
Jun 28, 2014·BioMed Research International·Hyun-Soon KimKisung Ko
Sep 22, 2012·Human Vaccines & Immunotherapeutics·Qiang Chen, Huafang Lai
Sep 9, 2016·Immunotherapy·Charu Aggarwal
Oct 28, 2016·GM Crops & Food
Aug 14, 2010·Acta Biochimica Et Biophysica Sinica·Shanli ZhuLifang Zhang
Feb 6, 2017·Trends in Biotechnology·Alejandra Wong-ArceSergio Rosales-Mendoza
Oct 7, 2010·Expert Review of Vaccines·António RoldãoPaula M Alves
Nov 3, 2011·Expert Review of Vaccines·Luigi BuonaguroFranco M Buonaguro
Apr 18, 2015·Expert Review of Vaccines·Sergio Rosales-Mendoza, Dania O Govea-Alonso
Aug 3, 2010·Expert Review of Vaccines·Rurick K SalyaevNatalya I Rekoslavskaya
Oct 20, 2018·Frontiers in Immunology·Rashmirekha PatiAvinash Sonawane
Nov 26, 2020·International Journal of Molecular Sciences·Julio Angel Vázquez-MartínezVianney Ortiz-Navarrete
May 19, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Neda RahimianHamed Mirzaei
Aug 17, 2021·Biotechnology and Bioprocess Engineering : BBE·Siddhesh B GhagVishwas A Bapat

❮ Previous
Next ❯

Methods Mentioned

BETA
electrophoresis
Transgenic
ELISA
electron microscopy
PCR
transfection

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Antibodies: Agglutination

Antibody-mediated agglutination is the clumping of cells in the presence of antibody, which binds multiple cells together. This enhances the clearance of pathogens. Find the latest research on antibody-mediated agglutination here.